KEGG enrichment analysis revealed an enrichment of the NAFLD pathway, suggesting that SLXG may potentially treat nonalcoholic steatohepatitis (NASH) by regulating the expression of genes such as CXCL8, AKT1, SREBF1, IL6, PPARA, and ADIPOQ (Fig. 3B). The gene discussed is CXCL8; the disease is metabolic dysfunction-associated steatohepatitis.